IDYA
NASDAQ
US
IDEAYA Biosciences, Inc. - Common Stock
$32.74
▲ +$0.26
(+0.80%)
Vol 694K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.0B
ROE
-15.5%
Margin
-5.2%
D/E
0.00
Beta
0.09
52W
$13–$37
Wall Street Consensus
25 analysts · Apr 20269
Strong Buy
13
Buy
3
Hold
0
Sell
0
Strong Sell
88.0%
Buy Rating
Price Chart
Similar Stocks
TWST
Twist Bioscience Corp
$1.9B
CPRX
Catalyst Pharmaceuticals Inc
P/E 13.2
$2.9B
ARQT
Arcutis Biotherapeutics Inc
$3.6B
VERA
Vera Therapeutics, Inc
$3.5B
TVTX
Travere Therapeutics Inc
$3.4B
ORKA
Oruka Therapeutics Inc
$1.5B
VCYT
Veracyte Inc
P/E 110.3
$3.3B
BEAM
Beam Therapeutics Inc
$2.8B
IRON
Disc Medicine Inc
$3.0B
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.99 | $-0.94 | +$0.05 |
| Sep 2025 | $-0.56 | $1.33 | +$1.89 |
| Jun 2025 | $-0.81 | $-0.88 | $-0.08 |
| Mar 2025 | $-0.67 | $-0.82 | $-0.15 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $7.0M | — | — | $207.8M | $10.9M |
| Net Income | -$130.3M | -$71.4M | -$77.5M | $119.2M | -$83.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -31.4% | -31.4% | -31.4% | -31.4% | -15.5% | -15.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -1861.6% | -1861.6% | -1861.6% | -5.2% | -5.2% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 12.39 | 12.39 | 12.39 | 12.39 | 12.44 | 12.44 |
Key Ratios
ROA (TTM)
-14.4%
P/S (TTM)
14.11
P/B
2.1
EPS (TTM)
$-1.85
CF/Share
$-1.89
Rev Growth 3Y
-37.0%
52W High
$37.08
52W Low
$13.45
$13.45
52-Week Range
$37.08
Financial Health
Free Cash Flow
-$90.8M
Net Debt
-$84.9M
Cash
$112.8M
Total Debt
$27.9M
As of Dec 31, 2025
How does IDYA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IDYA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
14.1
▲
10%
above
peers
(12.9)
vs Peers
vs Industry
Fair value
P/B ratio
2.1
▼
15%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IDYA profitability vs Biotechnology peers
ROE
-15.5%
▲
77%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-5.2%
▲
98%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-14.4%
▲
69%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
IDYA financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
12.4
▲
180%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.1
▼
91%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
IDYA fundamentals radar
IDYA
Peer median
Industry
IDYA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IDYA vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
STEIN JEFFREY
Director · Mar 02
50000 shs
Last 90 days
Top Holders
Top 5: 44.23%FMR, LLC
14.97%
$409.5M
Blackrock Inc.
9.35%
$255.6M
Janus Henderson Group PLC
8.18%
$223.8M
Capital Research Global Inv…
6.01%
$164.4M
Vanguard Group Inc
5.72%
$156.3M
As of Dec 31, 2025
Latest News
No related news yet